Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HER-2/neu' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 669 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Liu, HL; Gandour-Edwards, R; Lara, PN; White, RD; LaSalle, JM
      Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization

      CANCER JOURNAL
    2. Sen, M; Wankowski, DM; Garlie, NK; Siebenlist, RE; Van Epps, D; LeFever, AV; Lum, LG
      Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors

      JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH
    3. Lui, VWY; He, YK; Goyal, K; Huang, L
      Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerheadribozyme results in growth inhibition of human ovarian carcinoma

      MOLECULAR THERAPY
    4. Di Modugno, F; Buglioni, S; Mottolese, M; Del Bello, D; Cascioli, S; Chersi, A; Santoni, A; Nistico, P
      Polyclonal antibodies against gp185(HER2) peptides: Their putative role inthe identification of a particular HER2 status in patients with breast cancer

      JOURNAL OF IMMUNOTHERAPY
    5. Schwaab, T; Lewis, LD; Cole, BF; Deo, Y; Fanger, MW; Wallace, P; Guyre, PM; Kaufman, PA; Heaney, JA; Schned, AR; Harris, RD; Ernstoff, MS
      Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI Xanti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu

      JOURNAL OF IMMUNOTHERAPY
    6. Hess, AD; Thoburn, C; Chen, WR; Miura, Y; Van der Wall, E
      The N-terminal flanking region of the invariant chain peptide augments theimmunogenicity of a cryptic "self" epitope from a tumor-associated antigen

      CLINICAL IMMUNOLOGY
    7. Cefai, D; Schwaninger, R; Balli, M; Brunner, T; Gimmi, CD
      Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy

      CELL DEATH AND DIFFERENTIATION
    8. Hatanaka, Y; Hashizume, K; Kamihara, Y; Itoh, H; Tsuda, H; Osamura, RY; Tani, Y
      Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest(TM) in breast carcinoma by image analysis

      PATHOLOGY INTERNATIONAL
    9. Tessier, DM; Matsumura, F
      Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment byselect pesticides

      TOXICOLOGICAL SCIENCES
    10. Buchler, P; Reber, HA; Buchler, MC; Roth, MA; Buchler, MW; Friess, H; Isacoff, WH; Hines, OJ
      Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)

      JOURNAL OF GASTROINTESTINAL SURGERY
    11. Houghton, RL; Dillion, DC; Molesh, DA; Zehentner, BK; Xu, JC; Jiang, J; Schmidt, C; Frudakis, A; Repasky, E; Maltez, A; Nolasco, M; Badaro, R; Zhang, XQ; Roche, PC; Persing, DH; Reed, SG
      Transcriptional complementarity in breast cancer: Application to detectionof circulating tumor cells

      MOLECULAR DIAGNOSIS
    12. DiGiovanna, MP
      Extracting functional information from tissues - Commentary

      MOLECULAR DIAGNOSIS
    13. Streckfus, C; Bigler, L; Dellinger, T; Dai, XL; Cox, WJ; McArthur, A; Kingman, A; Thigpen, JT
      Reliability assessment of soluble c-erbB-2 concentrations in the saliva ofhealthy women and men

      ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS
    14. Bange, J; Zwick, E; Ullrich, A
      Molecular targets for breast cancer therapy and prevention

      NATURE MEDICINE
    15. Hait, WN
      The prognostic and predictive values of ECD-HER-2

      CLINICAL CANCER RESEARCH
    16. Brabender, J; Danenberg, KD; Metzger, R; Schneider, PM; Park, JM; Salonga, D; Holscher, AH; Danenberg, PV
      Epidermal growth factor receptor and HER2-neu mRNA expression in non-smallcell lung cancer is correlated with survival

      CLINICAL CANCER RESEARCH
    17. Bergman, I; Barmada, MA; Griffin, JA; Slamon, DJ
      Treatment of meningeal breast cancer xenografts in the rat using an anti-P185/HER2 antibody

      CLINICAL CANCER RESEARCH
    18. Harris, LN; Yang, L; Liotcheva, V; Pauli, S; Iglehart, JD; Colvin, OM; Hsieh, TS
      Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy

      CLINICAL CANCER RESEARCH
    19. Le Naour, F; Misek, DE; Krause, MC; Deneux, L; Giordano, TJ; Scholl, S; Hanash, SM
      Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer

      CLINICAL CANCER RESEARCH
    20. McKee, GT; Tambouret, RH; Finkelstein, D
      A reliable method of demonstrating HER-2/neu, estrogen receptors, and progesterone receptors on routinely processed cytologic material

      APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
    21. Kaptain, S; Tan, LK; Chen, BY
      Her-2/neu and breast cancer

      DIAGNOSTIC MOLECULAR PATHOLOGY
    22. Skirnisdottir, I; Sorbe, B; Seidal, T
      The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    23. Fortin, A; Raybaud-Diogene, H; Tetu, B; Huot, J; Blondeau, L; Landry, J
      Markers of neck failure in oral cavity and oropharyngeal carcinomas treated with radiotherapy

      HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
    24. Disis, ML; Knutson, KL; McNeel, DG; Davis, D; Schiffman, K
      Clinical translation of peptide-based vaccine trials: The HER-2/neu model

      CRITICAL REVIEWS IN IMMUNOLOGY
    25. Prange, W; Schirmacher, P
      Absence of therapeutically relevant c-erbB-2 expression in human hepatocellular carcinomas

      ONCOLOGY REPORTS
    26. Arencibia, JM; Schally, AV; Krupa, M; Bajo, AM; Nagy, A; Szepeshazi, K; Plonowski, A
      Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness

      INTERNATIONAL JOURNAL OF ONCOLOGY
    27. Shinozaki, H; Okamoto, A; Shimizu, K; Saito, M; Yokota, J; Ochiai, K
      Absence of p51 alteration in human ovarian cancer

      INTERNATIONAL JOURNAL OF ONCOLOGY
    28. Manavi, M; Bauer, M; Baghestanian, M; Berger, A; Kucera, E; Pischinger, K; Battistutti, W; Czerwenka, K
      Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium

      TUMOR BIOLOGY
    29. Rovero, S; Boggio, K; Di Carlo, E; Amici, A; Quaglino, E; Porcedda, P; Musiani, P; Forni, G
      Insertion of the DNA for the 163-171 peptide of IL1 beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Heu-2/neu transgenic BALB/c mice

      GENE THERAPY
    30. Pupa, SM; Invernizzi, AM; Forti, S; Di Carlo, E; Musiani, P; Nanni, P; Lollini, PL; Meazza, R; Ferrini, S; Menard, S
      Prevention of spontaneous neu-expressing mammary tumor development in micetransgenic for rat proto-neu by DNA vaccination

      GENE THERAPY
    31. Kristiansen, G; Petersen, YYS; Kaufmann, O; Schluns, K; Dietel, M; Petersen, I
      Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer

      EUROPEAN JOURNAL OF CANCER
    32. Su, SJ; Lai, MD; Yeh, TM; Chow, NH
      Overexpression of HER-2/neu enhances the sensitivity of human bladder cancer cells to urinary isoflavones

      EUROPEAN JOURNAL OF CANCER
    33. Cooke, T; Reeves, J; Lannigan, A; Stanton, P
      The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker

      EUROPEAN JOURNAL OF CANCER
    34. van de Vijver, MJ
      Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)

      EUROPEAN JOURNAL OF CANCER
    35. Yang, HY; Shao, RP; Hung, MC; Lee, MH
      p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis

      ONCOGENE
    36. Brodie, SG; Xu, XL; Li, CL; Kuo, A; Leder, P; Deng, CX
      Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis

      ONCOGENE
    37. Rait, AS; Pirollo, KF; Rait, V; Krygier, JE; Xiang, LM; Chang, EH
      Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer

      CANCER GENE THERAPY
    38. Pinto, AE; Andre, S; Pereira, T; Nobrega, S; Soares, J
      c-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis

      ANNALS OF ONCOLOGY
    39. Fountzilas, G; Tsavdaridis, D; Kalogera-Fountzila, A; Christodoulou, C; Timotheadou, E; Kalofonos, C; Kosmidis, P; Adamou, A; Papakostas, P; Gogas, H; Stathopoulos, G; Razis, E; Bafaloukos, D; Skarlos, D
      Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer - A Hellenic Cooperative Oncology Group phase IIstudy

      ANNALS OF ONCOLOGY
    40. Cooke, T; Reeves, J; Lanigan, A; Stanton, P
      HER2 as a prognostic and predictive marker for breast cancer

      ANNALS OF ONCOLOGY
    41. Valagussa, P
      HER2 status: A statistician's view

      ANNALS OF ONCOLOGY
    42. Baselga, J
      Phase I and II clinical trials of trastuzumab

      ANNALS OF ONCOLOGY
    43. Scholl, S; Beuzeboc, P; Pouillart, P
      Targeting HER2 in other tumor types

      ANNALS OF ONCOLOGY
    44. Matsuyama, S; Nakamura, M; Yonezawa, K; Shimada, T; Ohashi, F; Takamori, Y; Kubo, K
      Expression patterns of the erbB subfamily mRNA in canine benign and malignant mammary tumors

      JOURNAL OF VETERINARY MEDICAL SCIENCE
    45. Hanna, WM; Kahn, HJ; Pienkowska, M; Blondal, J; Seth, A; Marks, A
      Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting

      MODERN PATHOLOGY
    46. Hirashima, N; Takahashi, W; Yoshii, S; Yamane, T; Ooi, A
      Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: A comparative immunohistochemical and fluorescence in situ hybridization study

      MODERN PATHOLOGY
    47. Schnitt, SJ
      Breast cancer in the 21st century: Neu opportunities and neu challenges

      MODERN PATHOLOGY
    48. Muller-Hocker, J; Zietz, C; Sendelhofert, A
      Deregulated expression of cell cycle-associated proteins in solid pseudopapillary tumor of the pancreas

      MODERN PATHOLOGY
    49. Thomson, TA; Hayes, MM; Spinelli, JJ; Hilland, E; Sawrenko, C; Phillips, D; Dupuis, B; Parker, RL
      HER-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization

      MODERN PATHOLOGY
    50. Rummukainen, JK; Salminen, T; Lundin, J; Kytola, S; Joensuu, H; Isola, JJ
      Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array

      MODERN PATHOLOGY
    51. Golijow, CD; Abba, M; Mouron, SA; Gomez, MA; Guercci, A; Dulout, FN
      Detection of c-erbB-2 gene amplification in cervical scrapes positive for human papillomavirus (HPV)

      CANCER INVESTIGATION
    52. Ross, JS; McKenna, BJ
      The HER-2/neu oncogene in tumors of the gastrointestinal tract

      CANCER INVESTIGATION
    53. Bast, RC; Ravdin, P; Hayes, DF; Bates, S; Fritsche, H; Jessup, JM; Kemeny, N; Locker, GY; Mennel, RG; Somerfield, MR
      2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology

      JOURNAL OF CLINICAL ONCOLOGY
    54. Eppenberger-Castori, S; Kueng, W; Benz, C; Caduff, R; Varga, Z; Bannwart, F; Fink, D; Dietrich, H; Hohl, M; Muller, H; Paris, K; Schoumacher, F; Eppenberger, U
      Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay

      JOURNAL OF CLINICAL ONCOLOGY
    55. Ellis, MJ; Coop, A; Singh, B; Mauriac, L; Llombert-Cussac, A; Janicke, F; Miller, WR; Evans, DB; Dugan, M; Brady, C; Quebe-Fehling, E; Borgs, M
      Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial

      JOURNAL OF CLINICAL ONCOLOGY
    56. Hortobagyi, GN; Ueno, NT; Xia, WY; Zhang, S; Wolf, JK; Putnam, JB; Weiden, PL; Willey, JS; Carey, M; Branham, DL; Payne, JY; Tucker, SD; Bartholomeusz, C; Kilbourn, RG; De Jager, RL; Sneige, N; Katz, RL; Anklesaria, P; Ibrahim, NK; Murray, JL; Theriault, RL; Valero, V; Gershenson, DM; Bevers, MW; Huang, L; Lopez-Berestein, G; Hung, MC
      Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial

      JOURNAL OF CLINICAL ONCOLOGY
    57. Seidman, AD; Fornier, MN; Esteva, FJ; Tan, L; Kaptain, S; Bach, A; Panageas, KS; Arroyo, C; Valero, V; Currie, V; Gilewski, T; Theodoulou, M; Moynahan, ME; Moasser, M; Sklarin, N; Dickler, M; D'Andrea, G; Cristofanilli, M; Rivera, E; Hortobagyi, GN; Norton, L; Hudis, CA
      Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification

      JOURNAL OF CLINICAL ONCOLOGY
    58. Tubbs, RR; Pettay, JD; Roche, PC; Stoler, MH; Jenkins, RB; Grogan, TM
      Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message

      JOURNAL OF CLINICAL ONCOLOGY
    59. Halperin, R; Zehavi, S; Habler, L; Hadas, E; Bukovsky, I; Schneider, D
      Comparative immunohistochemical study of endometrioid and serous papillarycarcinoma of endometrium

      EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
    60. Shen, M; Feng, YJ; Ge, BQ; Wu, ZJ; Zhu, MW
      Liposome-C-erbB(2) antisense oligodoxynucleotides in human ovarian cancer cells

      CHINESE MEDICAL JOURNAL
    61. Krogerus, LA; Leivonen, M
      HER-2/neu oncogene expression in advanced breast cancer

      CANCER DETECTION AND PREVENTION
    62. Skalova, A; Starek, I; Kucerova, V; Szepe, P; Plank, L
      Salivary duct carcinoma - A highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression

      PATHOLOGY RESEARCH AND PRACTICE
    63. Li, Z; Xia, WY; Fang, BL; Yan, DH
      Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression

      CANCER LETTERS
    64. Puri, R; Tousson, A; Chen, LL; Kakar, SS
      Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors

      CANCER LETTERS
    65. Coronado, PJ; Vidart, JA; Lopez-asenjo, JA; Fasero, M; Furio-bacete, V; Magrina, J; Escudero, M
      P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression

      EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY
    66. Ficorella, C
      Docetaxel (Taxotere (R)) combined with trastuzumab (Herceptin)

      TUMORI
    67. Mokbel, K; Hassanally, D
      From HER2 to herceptin

      CURRENT MEDICAL RESEARCH AND OPINION
    68. Safran, H; Steinhoff, M; Mangray, S; Rathore, R; King, TC; Chai, L; Berzein, K; Moore, T; Iannitti, D; Reiss, P; Pasquariello, T; Akerman, P; Quirk, D; Mass, R; Goldstein, L; Tantravahi, U
      Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    69. Halperin, R; Zehavi, S; Hadas, E; Habler, L; Bukovsky, I; Schneider, D
      Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
    70. Vang, R; Whitaker, BP; Farhood, AI; Silva, EG; Ro, JY; Deavers, MT
      Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
    71. Korkolis, D; Ardavanis, A; Yotis, J; Kyroudi, A; Gorgoulis, V; Kittas, C
      HER-2/neu overexpression in breast cancer: An immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein andcathepsin-D

      ANTICANCER RESEARCH
    72. Cook, GB; Neaman, IE; Goldblatt, JL; Cambetas, DR; Hussain, M; Luftner, D; Yeung, KK; Chan, DW; Schwartz, MK; Allard, WJ
      Clinical utility of scram HER-2/neu testing on the Bayer Immuno 1 (R) automated system in breast cancer

      ANTICANCER RESEARCH
    73. Fiche, M
      Fluorescence in situ hybridization (FISH): current developments and prospects in pathology

      ANNALES DE PATHOLOGIE
    74. Janocko, LE; Brown, KA; Smith, CA; Gu, LP; Pollice, AA; Singh, SG; Julian, T; Wolmark, N; Sweeney, L; Silverman, JF; Shackney, SE
      Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplificationby fluorescence in situ hybridization in primary human breast cancers

      CYTOMETRY
    75. Prechtel, K; Prechtel, D
      Current standards for the diagnosis of breast carcinoma in routine pathology practice

      PATHOLOGE
    76. Potti, A; Ganti, AK; Koch, M; Mehdi, SA; Levitt, R
      Identification of HER-2/neu overexpression and the clinical course of lungcarcinoma in non-smokers with chronic lymphocytic leukemia

      LUNG CANCER
    77. Mueller-Holzner, E; Fink, V; Frede, T; Marth, C
      Immunohistochemical determination of HER2 expression in breast cancer fromcore biopsy specimens: a reliable predictor of HEr2 status of the whole tumor

      BREAST CANCER RESEARCH AND TREATMENT
    78. Konecny, G; Fritz, M; Untch, M; Lebeau, A; Felber, M; Lude, S; Beryt, M; Hepp, H; Slamon, D; Pegram, M
      HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

      BREAST CANCER RESEARCH AND TREATMENT
    79. Small, EJ; Bok, R; Reese, DM; Sudilovsky, D; Frohlich, M
      Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer

      SEMINARS IN ONCOLOGY
    80. Muss, HB
      Role of adjuvant endocrine therapy in early-stage breast cancer

      SEMINARS IN ONCOLOGY
    81. Duska, LR; Garrett, A; Rueda, BR; Haas, J; Chang, YC; Fuller, AF
      Endometrial cancer in women 40 years old or younger

      GYNECOLOGIC ONCOLOGY
    82. Campos, SM; Penson, RT; Mays, AR; Berkowitz, RS; Fuller, AF; Goodman, A; Matulonis, UA; Muzikansky, A; Seiden, MV
      The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

      GYNECOLOGIC ONCOLOGY
    83. de Pender, AMG; Alers, JC; Vissers, KJ; de Both, NJ; Dinjens, WNM; van Dekken, H
      Evaluation of oncogene amplification in intact and truncated cell nuclei of gastro-esophageal cancer cell lines by DNA in situ hybridisation

      ACTA HISTOCHEMICA
    84. Hanna, W
      Testing for HER2 status

      ONCOLOGY
    85. Menard, S; Fortis, S; Castiglioni, F; Agresti, R; Balsari, A
      HER2 as a prognostic factor in breast cancer

      ONCOLOGY
    86. Piccart, M; Lohrisch, C; Di Leo, A; Larsimont, D
      The predictive value of HER2 in breast cancer

      ONCOLOGY
    87. Akatsuka, T; Wada, T; Kokai, Y; Sawada, N; Yamawaki, S; Ishii, S
      Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma

      ONCOLOGY
    88. Novotny, J; Petruzelka, L; Vedralova, J; Kleibl, Z; Matous, B; Judas, L
      Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients

      NEOPLASMA
    89. Rummukainen, JK; Salminen, T; Lundin, J; Joensuu, H; Isola, JJ
      Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples

      LABORATORY INVESTIGATION
    90. Bartlett, JMS; Going, JJ; Mallon, EA; Watters, AD; Reeves, JR; Stanton, P; Richmond, J; Donald, B; Ferrier, R; Cooke, TG
      Evaluating HER2 amplification and overexpression in breast cancer

      JOURNAL OF PATHOLOGY
    91. Pilon, SA; Piechocki, MP; Wei, WZ
      Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

      JOURNAL OF IMMUNOLOGY
    92. zum Buschenfelde, CM; Metzger, J; Hermann, C; Nicklisch, N; Peschel, C; Bernhard, H
      The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells

      JOURNAL OF IMMUNOLOGY
    93. Yip, YL; Smith, G; Koch, J; Dubel, S; Ward, RL
      Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: Implications for vaccine design

      JOURNAL OF IMMUNOLOGY
    94. Soares, MM; Mehta, V; Finn, OJ
      Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection

      JOURNAL OF IMMUNOLOGY
    95. Wallace, PK; Kaufman, PA; Lewis, LD; Keler, T; Givan, AL; Fisher, JL; Waugh, MG; Wahner, AE; Guyre, PM; Fanger, MW; Ernstoff, MS
      Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo

      JOURNAL OF IMMUNOLOGICAL METHODS
    96. Nanni, P; Nicoletti, G; De Giovanni, C; Landuzzi, L; Di Carlo, E; Cavallo, F; Pupa, SM; Rossi, I; Colombo, MP; Ricci, C; Astolfi, A; Musiani, P; Forni, G; Lollini, PL
      Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

      JOURNAL OF EXPERIMENTAL MEDICINE
    97. Khan, AJ; DiGiovanna, MP; Ross, DA; Sasaki, CT; Carter, D; Son, YH; Haffty, BG
      Adenoid cystic carcinoma: A retrospective clinical review

      INTERNATIONAL JOURNAL OF CANCER
    98. Uno, M; Otsuki, T; Kurebayashi, J; Sakaguchi, H; Isozaki, Y; Ueki, A; Yata, K; Fujii, T; Hiratsuka, J; Akisada, T; Harada, T; Imajo, Y
      Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma

      INTERNATIONAL JOURNAL OF CANCER
    99. Tanaka, Y; Amos, KD; Joo, HG; Eberlein, TJ; Goedegebuure, PS
      Modification of the HER2/neu-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes

      INTERNATIONAL JOURNAL OF CANCER
    100. Maletz, K; Kufer, P; Mack, M; Raum, T; Pantel, K; Riethmuller, G; Gruber, R
      Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity

      INTERNATIONAL JOURNAL OF CANCER


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/05/20 alle ore 23:15:18